Recommendation from Electricals and Healthcare Sector

The scrips in this column have been recommended with a 15-day investment horizon in mind and carry high risk. Therefore, investors are advised to take into account their risk appetite before investing, as fundamentals may or may not back the recommendations.[EasyDNNnews:PaidContentStart]

Olectra Greentech Ltd.
CMP - ₹1,234.70
BSE CODE 532439
Volume 26,885
Face Value ₹4
Target ₹1,335 - ₹1,360
Stoploss ₹1,150 (CLS)

Olectra Greentech Ltd is a pioneer in electric bus manufacturing and composite insulators in India. The company focuses on sustainable mobility through high-performance electric buses and green technologies. During Q3FY26, the company reported a strong performance, with revenue surging 29 per cent year-on-year to ₹664 crore. Profitability remained steady at ₹47 crore, in line with the same quarter last year. The company continues to secure strong order inflows from government bodies, reflecting its leadership in India’s electric bus segment. In February, it received a major order from Telangana State Road Transport Corporation (TGSRTC) for supply, operation, and maintenance of 1,085 electric buses. The value of the supply for these electric buses is estimated to be around ₹1,800 crore. With the government’s increasing focus on renewable and clean mobility, the company is well positioned for sustained growth. Given its robust Order Book and favourable industry tailwinds, we recommend BUY.

Strides Pharma Science Ltd.
CMP - ₹1,097.55
BSE CODE 532531
Volume 22,412
Face Value ₹10
Target ₹1,185- ₹1,205
Stoploss ₹1,020 (CLS)

S trides Pharma Science Ltd is a global pharmaceutical company engaged in the development and manufacturing of niche generic formulations. It has a strong presence across regulated and emerging markets, with operations in over 100 countries. The company focuses on complex dosage forms, supported by a robust manufacturing and R&D infrastructure, driving its global growth strategy. The stock has recently witnessed strong buying interest, rallying 16-18 per cent over the past month and delivering around 35 per cent returns over the last six months, showcasing resilience amid a weak broader market. As of March 2026, DIIs increased their stake to 14.44 per cent, while renowned investor Mukul Agrawal held a 1.16 per cent stake. The company is poised for strong growth driven by improving U.S. generics traction, expanding product pipeline, and enhanced operational efficiencies. Strategic focus on regulated markets and margin recovery further strengthens earnings visibility, supporting a positive future outlook; hence we recommend BUY.

[EasyDNNnews:PaidContentEnd] [EasyDNNnews:UnPaidContentStart]

[EasyDNNnews:UnPaidContentEnd]